In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19

• DOI: 10.3389/fphar.2021.598925
• Publication Date: 2021-02-26T04:26:47Z
• Authors: Andrés López-Cortés; Patricia Guevara-...; Nikolaos C. Kyria...; Carlos Barba-Ostria; Ángela León Cáceres; Santiago Guerrero; Esteban Ortiz-Prado; Cristian R. Munteanu; Eduardo Tejera; Doménica Cevallos...; Ana María Gómez-J...; Katherine Simbaña...; Adriana Granizo-M...; Gabriela Pérez-M; Silvana Moreno; Jennyfer M. Garcí...; Ana Karina Zambrano; Yunierkis Pérez-C...; Alejandro Cabrera...; Lourdes Puig San ...; Carolina Proaño-C...; Jhommara Bautista; Andreina Quevedo; Nelson Varela; Luis Abel Quiñones; César Paz-y-Miño
• Keywords: Drug repositioning; Interactome; Repurposing

Background: There is pressing urgency to identify therapeutic targets and drugs that allow treating COVID-19 patients effectively. Methods: We performed in silico analyses of immune system protein interactome network, single-cell RNA sequencing human tissues, artificial neural networks reveal potential for drug repurposing against COVID-19. Results: screened 1,584 high-confidence proteins ACE2 TMPRSS2 co-expressing cells, finding 25 significantly overexpressed nasal goblet secretory lung type II pneumocytes, ileal absorptive enterocytes with several immunopathologies. Then, we fully connected deep find the best multitask classification model predict activity 10,672 drugs, obtaining approved compounds under investigation, experimental highest area receiver operating characteristics. Conclusion: After being effectively analyzed clinical trials, these can be considered treatment severe patients. Scripts downloaded at https://github.com/muntisa/immuno-drug-repurposing-COVID-19 .